Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer

Keyphrases

• Lung Cancer 100%
• Tumor Progression 100%
• Mouse Model 100%
• Cisplatin 100%
• Cisplatin Treatment 100%
• Damage Repair 100%
• Drug-resistant Tumor 100%
• In Cancer 50%
• Genetic Approach 50%
• DNA Repair 50%
• Cancer Treatment 50%
• Lung Tumor 50%
• Genetic Modification 50%
• DNA Damage 50%
• Cell Cycle Arrest 50%
• Tumor Protein p53 (TP53) 50%
• Imaging Approach 50%
• Chemotherapy Resistance 50%
• Apoptosis Induction 50%
• Patient-specific Treatment 50%
• Evolutionary Genomics 50%
• Transcriptional Targets 50%
• Tumor Burden 50%
• Genomic Approaches 50%
• Death Domain 50%
• Human Non-small Cell Lung Cancer 50%
• Genetic Imaging 50%
• Platinum Analogs 50%
• Human Lung Tumors 50%
• Chemotherapy Response 50%
• Multiple Mice 50%
• Repair Capacity 50%
• Cisplatin Resistance 50%
• Response Mechanism 50%
• Histopathology 50%
• Elevated Levels 50%
• Cell Cycle Arrest Apoptosis 50%
• Lung Tumor Cell 50%

Biochemistry, Genetics and Molecular Biology

• Tumor Progression 100%
• Mouse Model 100%
• Cisplatin 100%
• P53 40%
• Cell Cycle Arrest 40%
• Cell Cycle Checkpoint 40%
• Genomics 40%
• Genetics 20%
• P21 20%
• DNA Repair 20%
• Tumor Suppressor Protein 20%
• DNA Damage 20%
• Tumor Volume 20%
• Death Domain 20%
• Programmed Cell Death 20%

Immunology and Microbiology

• Mouse Model 100%
• Lung 100%
• P53 50%
• Cell Cycle Arrest 50%
• Cell Cycle Checkpoint 50%
• Tumor Cell 25%
• DNA Repair 25%
• DNA Damage 25%
• Tumor Volume 25%
• Death Domain 25%
• Programmed Cell Death 25%